Replies to post #520119 on NorthWest Biotherapeutics Inc (NWBO)

[supersteve13]

yes- and it would reduce competition for trial-eligible patients by different trials. I work in this space and it's a real problem, especially in cancers with incidence < 75,000 per year in US (for example).

[OilPatch]

Great... thanks for your opinion.